<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3678">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419535</url>
  </required_header>
  <id_info>
    <org_study_id>110208</org_study_id>
    <secondary_id>11-CH-0208</secondary_id>
    <secondary_id>ZIADK075121</secondary_id>
    <nct_id>NCT01419535</nct_id>
  </id_info>
  <brief_title>Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults</brief_title>
  <official_title>Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Metabolic syndrome is a name given to a group of factors that tend to occur together.&#xD;
           These risk factors include central obesity (extra weight around the middle of the body)&#xD;
           and high blood pressure and blood sugar levels. They also include low levels of HDL&#xD;
           (&quot;good cholesterol&quot;) and high triglyceride levels. A person is said to have metabolic&#xD;
           syndrome if they have three or more of the above risk factors. People with metabolic&#xD;
           syndrome are at increased risk for type 2 diabetes, stroke, and heart disease.&#xD;
&#xD;
        -  Cortisol, a hormone produced by the adrenal glands, is an important regulator of&#xD;
           metabolism. People with central obesity and metabolic syndrome may have higher than&#xD;
           normal cortisol levels that the body cannot regulate properly. Abnormal cortisol levels&#xD;
           may play an important role in metabolic syndrome. Mifepristone is a drug that blocks&#xD;
           cortisol. Researchers are interested in studying its effects on metabolic syndrome.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To study the effects of short-term mifepristone treatment for metabolic syndrome.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Men and Women between 35 and 70 years of age are overweight or obese, and have abnormal&#xD;
      glucose and triglyceride levels.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. They will also&#xD;
           have blood and urine tests.&#xD;
&#xD;
        -  Participants will be admitted to the metabolic unit at the National Institutes of Health&#xD;
           Clinical Center for the first 3 days of the study:&#xD;
&#xD;
        -  Day 1: Body measurements (height, weight, waist, hip, and neck) and blood pressure&#xD;
           tests. Also, 24 hours of regular blood draws and 24-hour urine collection to monitor&#xD;
           regular daily cortisol levels.&#xD;
&#xD;
        -  Day 2: Glucose/insulin infusion test to measure blood sugar levels.&#xD;
&#xD;
        -  Day 3: Infusion of cortisol-like compounds and then regular blood draws for about 3&#xD;
           hours to evaluate how cortisol is metabolized.&#xD;
&#xD;
        -  At the end of Day 3, participants will receive mifepristone or a look-alike capsule to&#xD;
           take for 7 days at home.&#xD;
&#xD;
        -  After 7 days, participants will return to the metabolic unit to repeat the Day 1 and Day&#xD;
           2 study procedures. They will continue to take mifepristone.&#xD;
&#xD;
        -  One week after the second set of study tests, participants will return for a brief&#xD;
           physical exam and blood tests.&#xD;
&#xD;
        -  The study procedures will be repeated after 6 to 8 weeks, with the other study drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hormone cortisol is a key regulator of metabolism that influences the use of glucose&#xD;
      (sugar) and fat as fuels. Persistently increased cortisol levels, as in Cushing s syndrome,&#xD;
      lead to obesity, type 2 diabetes mellitus and lipid abnormalities including elevated&#xD;
      triglyceride levels and low high-density lipoprotein (HDL) levels. These same disorders are&#xD;
      also present in patients without Cushing s syndrome, suggesting that cortisol may be involved&#xD;
      in their pathogenesis. Mifepristone is a cortisol-like drug that blocks cortisol action in&#xD;
      the body. It can reverse lipid abnormalities, diabetes and obesity in Cushing s syndrome&#xD;
      patients but its effects on these conditions have not been tested in patients without the&#xD;
      syndrome.&#xD;
&#xD;
      The long-term aim of this clinical trial is to evaluate the ability of mifepristone to&#xD;
      reverse or improve glucose intolerance, dyslipidemia, hypertension and weight gain. An&#xD;
      initial 7-day prospective, randomized, placebo-controlled, crossover study is proposed here&#xD;
      to look at the effect of short-term administration of oral mifepristone or placebo on glucose&#xD;
      intolerance. Given that there are no human data available on the effect of mifepristone on&#xD;
      insulin sensitivity, this will be a pilot study of 15 subjects. Data from this study will&#xD;
      then be used to design a larger trial to evaluate long-term effects on blood pressure and&#xD;
      weight, as well as glucose and triglyceride control.&#xD;
&#xD;
      Overweight or obese subjects with abnormal glucose tolerance will undergo each of the two&#xD;
      treatments in a randomized order, including mifepristone by mouth and a look-alike inert&#xD;
      tablet by mouth. Each treatment study will include two or three days of baseline tests that&#xD;
      will be repeated after seven days of treatment. Treatments will be separated by at least six&#xD;
      and no more than eight weeks. The tests will include blood drawing, urine collection,&#xD;
      administration of glucose and insulin by vein, and a cortisol-like material to evaluate the&#xD;
      metabolism of cortisol and a related hormone, corticosterone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2011</start_date>
  <completion_date type="Actual">November 24, 2015</completion_date>
  <primary_completion_date type="Actual">November 24, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity Index</measure>
    <time_frame>Nine days</time_frame>
    <description>insulin sensitivity index based on the effect of insulin on glucose during frequently sampled intravenous glucose tolerance test (FSIVGTT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>Nine days</time_frame>
    <description>fasting plasma glucose after study agent compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin Levels</measure>
    <time_frame>9 days</time_frame>
    <description>Fasting insulin after study agent administration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>9 days</time_frame>
    <description>HOMA-IR is an index of insulin resistance, measured as glucose in mmol/L x insulin in mIU/mL)/22.5. HOMA-IR &gt; 2.5 indicates insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose-tissue Insulin Resistance Index (Adipo-IR)</measure>
    <time_frame>9 days</time_frame>
    <description>The adipose tissue insulin resistance index (Adipo-IR), a surrogate measure for fasting adipose-tissue insulin resistance, was calculated as the product of fasting insulin and fasting free fatty acids (FFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose-tissue Insulin Sensitivity Index (Adipo-SI)</measure>
    <time_frame>9 days</time_frame>
    <description>The Adipo-SI was calculated as ratio of the slope of the linear decrease in natural log transformed FFA [Ln (FFA) slope] during the first 90 minutes of the FSIVGTT and the area under the curve (AUC) of insulin during that 90-minute period (AUC Insulin 0-90 min).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Endocrine Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Mifepristone, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Mifepristone 50mg tablet by mouth every six hours for nine days.</description>
    <arm_group_label>Mifepristone, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Mifepristone</arm_group_label>
    <other_name>55245</other_name>
    <other_name>11β-[p-(Dimethylamino)phenyl]-17α-(1-propynyl)estra-4,9-dien-17β-ol-3-one</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.</description>
    <arm_group_label>Mifepristone, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Mifepristone</arm_group_label>
    <other_name>inert look-alike tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Men and women 35 - 70 years of age&#xD;
&#xD;
               2. Subjects will be overweight or obese, with body mass index (BMI) ranging from 25&#xD;
                  - 37 kg/m2.&#xD;
&#xD;
               3. Subjects will have either impaired fasting glucose (greater than or equal to 100&#xD;
                  mg/dL) or a 2-hour glucose value greater than or equal to 140 mg/dl during an&#xD;
                  oral glucose tolerance test (OGTT).&#xD;
&#xD;
                  OR&#xD;
&#xD;
                  Mild diabetes defined as patients with a Hemoglobin A1C (HbA1C) less than or&#xD;
                  equal to 7% on no medications (diet-controlled) or on a stable dose of metformin&#xD;
                  and no other hypoglycemic agents for greater than or equal to 3 months before&#xD;
                  study entry.&#xD;
&#xD;
               4. Willing and able to comply with study requirements.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Pregnancy and lactation&#xD;
&#xD;
          2. Diabetes requiring pharmacologic treatment. Diagnosis of diabetes will be based on the&#xD;
             2011 American Diabetes Association guidelines: HbA1C greater than or equal to 6.5%,&#xD;
             fasting plasma glucose greater than or equal to 126 mg/dl, 2-hour glucose greater than&#xD;
             or equal to 200 mg/dl during an OGTT, or a random blood glucose greater than or equal&#xD;
             to 200 mg/dl along with classic symptoms of hyperglycemia (34)&#xD;
&#xD;
          3. Uncontrolled hypertension (blood pressure greater than or equal to 180/110 mmHg)&#xD;
&#xD;
          4. Current unstable medical conditions including clinically significant impaired cardiac&#xD;
             function (Stage III and IV Cardiac failure), cardiac ischemia, severe respiratory&#xD;
             insufficiency requiring oxygen therapy as assessed on history and/or physical exam&#xD;
&#xD;
          5. Liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST)&#xD;
             more than 3-times the upper normal limit&#xD;
&#xD;
          6. Severe renal impairment (creatinine clearance &lt; 30 ml/min)&#xD;
&#xD;
          7. Evidence of human immunodeficiency virus (HIV) based on history and physical&#xD;
             examination and/or known positive HIV antibodies&#xD;
&#xD;
          8. Evidence of hepatitis C based on history and physical examination and/or known&#xD;
             positive hepatitis C (HCV) antibody&#xD;
&#xD;
          9. History of hemorrhagic disorders or on anticoagulants&#xD;
&#xD;
         10. History of endometrial cancer, endometrial hyperplasia, unexplained vaginal bleeding,&#xD;
             or endometrial thickness greater than 6 mm&#xD;
&#xD;
         11. Change in dose of lipid-lowering medications (including&#xD;
             3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A) inhibitors , fibrates,&#xD;
             niacin, ezetimibe, and over-the-counter fish oil supplements) within one month of&#xD;
             study entry and during the study period&#xD;
&#xD;
         12. Current administration of medications known to be strong CYP3A4 inhibitors including&#xD;
             ketoconazole, itraconazole, and erythromycin&#xD;
&#xD;
         13. Use of herbal supplements or grapefruit juice within 14 days of study drug initiation&#xD;
&#xD;
         14. Use of medications or dietary supplements that inhibit or induce CYP3A4 activity&#xD;
             within 14 days of study drug initiation&#xD;
&#xD;
         15. Use of oral, injectable, or inhaled glucocorticoids or megestrol in the past six&#xD;
             months&#xD;
&#xD;
         16. Use of estrogen-containing hormone therapy&#xD;
&#xD;
         17. Potential pseudocushing's states: depression or intake of &gt; 2 alcoholic drinks a day.&#xD;
             Subjects will be screened for depression using the well-validated physician health&#xD;
             questionnaire-9 (PHQ-9) with a score cut-off of greater than or equal to 10 for&#xD;
             moderate depression (35).&#xD;
&#xD;
         18. Subjects who are actively dieting or are in a weight loss program&#xD;
&#xD;
         19. Midnight salivary cortisol &gt; 100 ng/dl on two separate occasions&#xD;
&#xD;
         20. Untreated thyroid dysfunction (thyroid stimulating hormone and Free thyroxine (FT4)&#xD;
             not within normal range). If abnormal on screening labs, they will be repeated to&#xD;
             confirm that not due to lab error or non-thyroidal illness.&#xD;
&#xD;
         21. Moderate to severe anemia (hemoglobin &lt; 10 g/dl)&#xD;
&#xD;
         22. Blood donation of more than 500 ml within one month prior to study enrollment&#xD;
&#xD;
         23. Subjects with a prolonged corrected Q-T interval (QTc) on electrocardiogram&#xD;
&#xD;
         24. Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynnette K Nieman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-CH-0208.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am. 2005 Jun;34(2):327-39, viii. Review.</citation>
    <PMID>15850845</PMID>
  </reference>
  <reference>
    <citation>Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009 Aug;94(8):2692-701. doi: 10.1210/jc.2009-0370. Epub 2009 May 26. Review.</citation>
    <PMID>19470627</PMID>
  </reference>
  <reference>
    <citation>Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci. 2006 Nov;1083:111-28. Review.</citation>
    <PMID>17148736</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>March 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <keyword>Cortisol</keyword>
  <keyword>Hypercortisolism</keyword>
  <keyword>Glucose Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon reasonable request, individual participant data will be shared with other investigators</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Upon publication, for two years</ipd_time_frame>
    <ipd_access_criteria>plan for data use</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01419535/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01419535/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited to the study by advertisements and fliers. Sixty-three adults were evaluated at the single study site (the NIH Clinical Center) after providing informed consent. The first subject consented on November 11, 2011 and the final subject consented on April 16, 2015.</recruitment_details>
      <pre_assignment_details>Forty-four subjects were excluded; 31 had a normal oral glucose tolerance test and fasting glucose level, 2 exceeded BMI criterion, 2 exceeded HbA1C criterion, 2 had depression, and seven subjects had one of the following exclusion criteria: required insulin, &lt;35 years old, memory problems/compliance, abnormal thyroid function, drop out after screening, abnormal late night salivary cortisol, failure to complete screening. The remaining 19 subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone, Then Placebo</title>
          <description>Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.&#xD;
Mifepristone: Mifepristone 50mg tablet by mouth every six hours for nine days.&#xD;
Placebo: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Mifepristone</title>
          <description>Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.&#xD;
Mifepristone: Mifepristone 50mg tablet by mouth every six hours for nine days.&#xD;
Placebo: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>could not maintain iv line</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone, Then Placebo</title>
          <description>Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.&#xD;
Mifepristone: Mifepristone 50mg tablet by mouth every six hours for nine days.&#xD;
Placebo: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Mifepristone</title>
          <description>Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.&#xD;
Mifepristone: Mifepristone 50mg tablet by mouth every six hours for nine days.&#xD;
Placebo: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="6.5"/>
                    <measurement group_id="B2" value="52.8" spread="8.9"/>
                    <measurement group_id="B3" value="54.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.8" spread="15.8"/>
                    <measurement group_id="B2" value="102" spread="15.9"/>
                    <measurement group_id="B3" value="97.2" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/M^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="4.12"/>
                    <measurement group_id="B2" value="34.0" spread="2.37"/>
                    <measurement group_id="B3" value="32.4" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124" spread="16.1"/>
                    <measurement group_id="B2" value="133" spread="10.5"/>
                    <measurement group_id="B3" value="128" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.6" spread="4.7"/>
                    <measurement group_id="B2" value="76.9" spread="9.9"/>
                    <measurement group_id="B3" value="77.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>total cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.9" spread="59.0"/>
                    <measurement group_id="B2" value="184.3" spread="53.8"/>
                    <measurement group_id="B3" value="181.1" spread="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="7.5"/>
                    <measurement group_id="B2" value="40.0" spread="8.6"/>
                    <measurement group_id="B3" value="45.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.9" spread="41.3"/>
                    <measurement group_id="B2" value="108.3" spread="41.0"/>
                    <measurement group_id="B3" value="106.6" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>triglycerides</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.8" spread="88.3"/>
                    <measurement group_id="B2" value="180.0" spread="92.3"/>
                    <measurement group_id="B3" value="144.4" spread="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>free fatty acids</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.62" spread="0.18"/>
                    <measurement group_id="B2" value="0.54" spread="0.23"/>
                    <measurement group_id="B3" value="0.60" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fasting glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.0" spread="5.8"/>
                    <measurement group_id="B2" value="108.1" spread="20.6"/>
                    <measurement group_id="B3" value="104.6" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fasting insulin</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.7" spread="35.4"/>
                    <measurement group_id="B2" value="143.1" spread="43.3"/>
                    <measurement group_id="B3" value="109" spread="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>A1C</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="0.35"/>
                    <measurement group_id="B2" value="6.3" spread="0.49"/>
                    <measurement group_id="B3" value="6.1" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine free cortisol</title>
          <units>ug/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="23.0"/>
                    <measurement group_id="B2" value="18.1" spread="7.2"/>
                    <measurement group_id="B3" value="22.9" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity Index</title>
        <description>insulin sensitivity index based on the effect of insulin on glucose during frequently sampled intravenous glucose tolerance test (FSIVGTT)</description>
        <time_frame>Nine days</time_frame>
        <population>2 subjects in each group missing data due to iv line problems</population>
        <group_list>
          <group group_id="O1">
            <title>Post-mifepristone</title>
            <description>All subjects tested after mifepristone administration, compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>Post-placebo</title>
            <description>all subjects tested after placebo administration, compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity Index</title>
          <description>insulin sensitivity index based on the effect of insulin on glucose during frequently sampled intravenous glucose tolerance test (FSIVGTT)</description>
          <population>2 subjects in each group missing data due to iv line problems</population>
          <units>min-1·μU·ml-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="1.17"/>
                    <measurement group_id="O2" value="1.41" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures were analyzed by repeated-measures ANOVA including treatment group, time, and treatment*time interaction as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose</title>
        <description>fasting plasma glucose after study agent compared to baseline</description>
        <time_frame>Nine days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-mifepristone</title>
            <description>All subjects tested after mifepristone administration, compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>Post-placebo</title>
            <description>all subjects tested after placebo administration, compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose</title>
          <description>fasting plasma glucose after study agent compared to baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.4" spread="5.3"/>
                    <measurement group_id="O2" value="107.8" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures were analyzed by repeated-measures ANOVA including treatment group, time, and treatment*time interaction as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin Levels</title>
        <description>Fasting insulin after study agent administration compared to baseline</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-mifepristone</title>
            <description>All subjects tested after mifepristone administration, compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>Post-placebo</title>
            <description>all subjects tested after placebo administration, compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin Levels</title>
          <description>Fasting insulin after study agent administration compared to baseline</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" spread="76.1"/>
                    <measurement group_id="O2" value="142.8" spread="102.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures were analyzed by repeated-measures ANOVA including treatment group, time, and treatment*time interaction as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR is an index of insulin resistance, measured as glucose in mmol/L x insulin in mIU/mL)/22.5. HOMA-IR &gt; 2.5 indicates insulin resistance.</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-mifepristone</title>
            <description>All subjects tested after mifepristone administration, compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>Post-placebo</title>
            <description>all subjects tested after placebo administration, compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR is an index of insulin resistance, measured as glucose in mmol/L x insulin in mIU/mL)/22.5. HOMA-IR &gt; 2.5 indicates insulin resistance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="3.27"/>
                    <measurement group_id="O2" value="5.78" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures were analyzed by repeated-measures ANOVA including treatment group, time, and treatment*time interaction as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose-tissue Insulin Resistance Index (Adipo-IR)</title>
        <description>The adipose tissue insulin resistance index (Adipo-IR), a surrogate measure for fasting adipose-tissue insulin resistance, was calculated as the product of fasting insulin and fasting free fatty acids (FFA)</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-mifepristone</title>
            <description>All subjects tested after mifepristone administration, compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>Post-placebo</title>
            <description>all subjects tested after placebo administration, compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose-tissue Insulin Resistance Index (Adipo-IR)</title>
          <description>The adipose tissue insulin resistance index (Adipo-IR), a surrogate measure for fasting adipose-tissue insulin resistance, was calculated as the product of fasting insulin and fasting free fatty acids (FFA)</description>
          <units>mmol/l·μU/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" spread="45.9"/>
                    <measurement group_id="O2" value="65.5" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures were analyzed by repeated-measures ANOVA including treatment group, time, and treatment*time interaction as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose-tissue Insulin Sensitivity Index (Adipo-SI)</title>
        <description>The Adipo-SI was calculated as ratio of the slope of the linear decrease in natural log transformed FFA [Ln (FFA) slope] during the first 90 minutes of the FSIVGTT and the area under the curve (AUC) of insulin during that 90-minute period (AUC Insulin 0-90 min).</description>
        <time_frame>9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-mifepristone</title>
            <description>All subjects tested after mifepristone administration, compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>Post-placebo</title>
            <description>all subjects tested after placebo administration, compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose-tissue Insulin Sensitivity Index (Adipo-SI)</title>
          <description>The Adipo-SI was calculated as ratio of the slope of the linear decrease in natural log transformed FFA [Ln (FFA) slope] during the first 90 minutes of the FSIVGTT and the area under the curve (AUC) of insulin during that 90-minute period (AUC Insulin 0-90 min).</description>
          <units>ln(mmol /uU/mL*min)*10^8</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="32.9"/>
                    <measurement group_id="O2" value="42.8" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures were analyzed by repeated-measures ANOVA including treatment group, time, and treatment*time interaction as factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects returned for safety labs and discussion of any adverse events on approximately day 19 and day 33 after discontinuation of study agents.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Post-mifepristone</title>
          <description>All subjects tested after mifepristone administration, compared to baseline</description>
        </group>
        <group group_id="E2">
          <title>Post-placebo</title>
          <description>all subjects tested after placebo administration, compared to baseline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal blood chemistry</sub_title>
                <description>elevated alanine transferase less than one-fold above the upper limit of normal, resolved.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynnette Nieman MD</name_or_title>
      <organization>NIDDK, NIH</organization>
      <phone>301-496-8935</phone>
      <email>NiemanL@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

